Scholar Rock Holding (SRRK)

The company’s most advanced candidate is apitegromab, an investigational antibody designed to inhibit the latent form of myostatin, a protein that regulates muscle growth. By targeting myostatin activation rather than broadly blocking related pathways, Scholar Rock aims to improve muscle function while maintaining selectivity. A subcutaneous formulation of apitegromab is also in development, which could offer a more convenient administration option if approved.

Scholar Rock’s pipeline includes SRK-439, another fully human antibody aimed at pro- and latent myostatin with high potency and selectivity. The programme reflects the company’s broader strategy of using its understanding of growth factor biology to develop targeted medicines for rare, severe, and debilitating neuromuscular diseases.

The business is research and development-led, so its valuation is closely tied to clinical trial progress, regulatory milestones, manufacturing readiness, and the potential commercial role of its candidates alongside existing standards of care. For investors, Scholar Rock represents exposure to a specialised biotech platform focused on muscle biology and rare disease drug development, rather than a diversified pharmaceutical revenue base.